2023 Q2 Report: Global Trends in Biopharma Transactions
2023 Q2 Report: Global Trends in Biopharma Transactions Each quarter, Locust Walk’s deal team compiles key statistics and trends on […]
2023 Q2 Report: Global Trends in Biopharma Transactions Each quarter, Locust Walk’s deal team compiles key statistics and trends on […]
Deal Makers of Japan, Volume 3 The Deal Makers of Japan series aims to bridge the gap and offer insight
Podcast: Play in new window | Download (Duration: 11:08 — 12.2MB)
Subscribe: Apple Podcasts | Spotify | RSS
This episode of Biotalk is focused on Locust Walk’s 2023 First Quarter Market Conditions Report, in which we apply the latest
2023 Q1 Report: Global Trends in Biopharma Transactions Each quarter, Locust Walk’s deal team compiles key statistics and trends on
Podcast: Play in new window | Download (Duration: 41:12 — 45.4MB)
Subscribe: Apple Podcasts | Spotify | RSS
On this episode of Biotalk, Locust Walk welcomes Andrew Allen, M.D., Ph.D., Co-Founder, President, CEO, and board member of Gritstone
RNA Therapeutics Landscape Overview Locust Walk views RNA therapeutics in 5 key pillars: RNA Translation Inhibition Protein Expression RNA-Targeting Small
RNA Therapeutics Landscape Overview Locust Walk views RNA therapeutics in 5 key pillars: RNA Translation Inhibition Protein Expression RNA-Targeting Small
Podcast: Play in new window | Download (Duration: 13:12 — 14.7MB)
Subscribe: Apple Podcasts | Spotify | RSS
Our first Biotalk podcast is focused on Locust Walk’s 2022 year-in-review market conditions, which was released the first day of JPMorgan
2022 Year In Review Report: Global Trends in Biopharma Transactions Each quarter, Locust Walk’s deal team compiles key statistics and